trandolapril ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 2712 87679-37-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trandolapril
  • gopten
  • mavik
  • odrik
The effect of trandolapril in hypertension appears to result primarily from the inhibition of circulating and tissue ACE activity thereby reducing angiotensin II formation, decreasing vasoconstriction, decreasing aldosterone secretion, and increasing plasma renin. Decreased aldosterone secretion leads to diuresis, natriuresis, and a small increase of serum potassium. Trandolapril is deesterified to the diacid metabolite, trandolaprilat, which is approximately eight times more active as an inhibitor of ACE activity.
  • Molecular weight: 430.55
  • Formula: C24H34N2O5
  • CLOGP: 2.10
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -4.32
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.06 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 10 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.25 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.17 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.26 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 26, 1996 FDA ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paranoia 61.67 18.86 23 3221 11656 63474122
Hallucination, auditory 59.57 18.86 23 3221 12801 63472977
Lactic acidosis 56.74 18.86 31 3213 38256 63447522
Psychotic disorder 56.04 18.86 27 3217 25685 63460093
Focal segmental glomerulosclerosis 49.00 18.86 12 3232 1456 63484322
Cerebellar haematoma 39.89 18.86 8 3236 387 63485391
Endometrial ablation 37.93 18.86 9 3235 955 63484823
Red blood cells urine positive 35.73 18.86 11 3233 3115 63482663
Bacterial test 31.21 18.86 8 3236 1166 63484612
Hyperaesthesia 30.44 18.86 13 3231 9345 63476433
White blood cells urine positive 30.33 18.86 11 3233 5147 63480631
Acute kidney injury 27.97 18.86 49 3195 263366 63222412
Urine abnormality 27.03 18.86 11 3233 7008 63478770
Asthma 25.54 18.86 32 3212 127529 63358249
Vaginal discharge 24.17 18.86 11 3233 9187 63476591
Cardiogenic shock 22.42 18.86 13 3231 17919 63467859
Organising pneumonia 22.07 18.86 9 3235 5767 63480011
Dorsal ramus syndrome 21.12 18.86 4 3240 143 63485635
Dyspnoea 20.50 18.86 77 3167 661236 62824542
Angioedema 20.38 18.86 18 3226 47947 63437831
HLA-B*27 positive 19.62 18.86 4 3240 210 63485568
Palindromic rheumatism 19.42 18.86 4 3240 221 63485557

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oesophageal obstruction 75.55 19.03 16 3609 492 34952814
Bezoar 62.44 19.03 16 3609 1141 34952165
Arterial disorder 37.92 19.03 11 3614 1248 34952058
Oesophageal haemorrhage 28.83 19.03 9 3616 1309 34951997
Reading disorder 26.78 19.03 7 3618 539 34952767
Wrong product administered 25.50 19.03 12 3613 5322 34947984
Jugular vein distension 25.41 19.03 7 3618 659 34952647
Hypotension 23.73 19.03 63 3562 221586 34731720
Waist circumference increased 23.28 19.03 7 3618 899 34952407
White coat hypertension 22.87 19.03 5 3620 179 34953127
Eosinophil count increased 22.78 19.03 13 3612 8559 34944747
Body mass index increased 22.10 19.03 7 3618 1068 34952238
Cough 21.76 19.03 48 3577 150092 34803214
Bronchial wall thickening 20.44 19.03 7 3618 1361 34951945
Dysgraphia 20.39 19.03 8 3617 2279 34951027
Enterobacter pneumonia 20.12 19.03 4 3621 89 34953217

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oesophageal obstruction 69.10 16.66 16 6115 1010 79737247
Lactic acidosis 60.17 16.66 47 6084 70312 79667945
Bezoar 53.82 16.66 16 6115 2672 79735585
Paranoia 41.42 16.66 23 6108 19409 79718848
Hallucination, auditory 40.07 16.66 23 6108 20670 79717587
Reading disorder 38.75 16.66 10 6121 992 79737265
Arterial disorder 36.19 16.66 11 6120 1979 79736278
Psychotic disorder 36.12 16.66 28 6103 41374 79696883
Endometrial ablation 34.96 16.66 9 6122 884 79737373
Acute kidney injury 33.90 16.66 102 6029 519302 79218955
Cerebellar haematoma 32.83 16.66 8 6123 628 79737629
Hyperkalaemia 30.99 16.66 41 6090 114357 79623900
Oesophageal haemorrhage 28.88 16.66 9 6122 1758 79736499
Bacterial test 27.65 16.66 8 6123 1215 79737042
Red blood cells urine positive 26.37 16.66 11 6120 4952 79733305
Hypoglycaemia 25.37 16.66 35 6096 101559 79636698
Dysgraphia 25.06 16.66 10 6121 4022 79734235
White blood cells urine positive 24.23 16.66 11 6120 6064 79732193
Cough 23.85 16.66 72 6059 366717 79371540
Vaginal discharge 22.07 16.66 11 6120 7452 79730805
Jugular vein distension 22 16.66 7 6124 1463 79736794
Hypotension 21.97 16.66 79 6052 440238 79298019
Urine abnormality 21.07 16.66 11 6120 8208 79730049
Waist circumference increased 21.04 16.66 7 6124 1682 79736575
Body mass index increased 20.12 16.66 7 6124 1926 79736331
Focal segmental glomerulosclerosis 19.82 16.66 8 6123 3313 79734944
Cardiogenic shock 19.76 16.66 20 6111 41894 79696363
Hyperaesthesia 19.52 16.66 12 6119 12210 79726047
Enterobacter pneumonia 19.33 16.66 4 6127 149 79738108
Libido decreased 19.23 16.66 9 6122 5312 79732945
Coagulopathy 18.49 16.66 18 6113 35988 79702269
Eosinophil count increased 18.11 16.66 13 6118 17092 79721165
Combined pulmonary fibrosis and emphysema 18.05 16.66 3 6128 32 79738225
Bronchial wall thickening 17.99 16.66 7 6124 2634 79735623
Itching scar 17.65 16.66 3 6128 37 79738220
White coat hypertension 16.70 16.66 5 6126 855 79737402

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA10 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BB10 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA MoA N0000000181 Angiotensin-converting Enzyme Inhibitors
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35457 ACE inhibitor
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:76967 human xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Left ventricular cardiac dysfunction indication 429589006
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Hyperkalemia contraindication 14140009
Ventricular tachycardia contraindication 25569003
Complete atrioventricular block contraindication 27885002
Acute cerebrovascular insufficiency contraindication 29322000
Sick sinus syndrome contraindication 36083008 DOID:13884
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Low cardiac output syndrome contraindication 44088000
Low blood pressure contraindication 45007003
Bradycardia contraindication 48867003
Lown-Ganong-Levine syndrome contraindication 55475008 DOID:13087
Aortic valve stenosis contraindication 60573004 DOID:1712
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Transplantation contraindication 77465005
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Second degree atrioventricular block contraindication 195042002
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Neuromuscular Transmission Deficiency contraindication
Hemodialysis with High-Flux Membrane contraindication
First Degree Atrioventricular Heart Block contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.23 acidic
pKa2 5.77 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 8.12 WOMBAT-PK CHEMBL

External reference:

IDSource
4020971 VUID
N0000148444 NUI
D00383 KEGG_DRUG
4020971 VANDF
C0076891 UMLSCUI
CHEBI:9649 CHEBI
CHEBI:141521 CHEBI
X93 PDB_CHEM_ID
CHEMBL1519 ChEMBL_ID
DB00519 DRUGBANK_ID
C052035 MESH_SUPPLEMENTAL_RECORD_UI
5484727 PUBCHEM_CID
6453 IUPHAR_LIGAND_ID
C061095 MESH_SUPPLEMENTAL_RECORD_UI
5746 INN_ID
1T0N3G9CRC UNII
DB14209 DRUGBANK_ID
1546379 RXNORM
107488 MMSL
5448 MMSL
5606 MMSL
5642 MMSL
d04008 MMSL
004452 NDDF
108562001 SNOMEDCT_US
386871006 SNOMEDCT_US
C0165477 UMLSCUI
CHEMBL1201387 ChEMBL_ID
6370 INN_ID
87679-71-8 SECONDARY_CAS_RN
5464097 PUBCHEM_CID
6455 IUPHAR_LIGAND_ID
RR6866VL0O UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 42806-052 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 42806-053 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 42806-054 TABLET 4 mg ORAL ANDA 18 sections
Trandolapril Human Prescription Drug Label 1 50090-4120 TABLET 2 mg ORAL ANDA 21 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 50090-4128 TABLET 1 mg ORAL ANDA 19 sections
Mavik HUMAN PRESCRIPTION DRUG LABEL 1 54868-5099 TABLET 4 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 54868-5311 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 54868-5320 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 54868-5548 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL NDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 54868-6061 TABLET 4 mg ORAL ANDA 14 sections
Trandolapril Human Prescription Drug Label 1 57237-089 TABLET 1 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 57237-090 TABLET 2 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 57237-091 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 63629-8003 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 63629-8390 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-164 TABLET 1 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-164 TABLET 1 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-165 TABLET 2 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-165 TABLET 2 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-166 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-166 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68151-0757 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-566 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-567 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-568 TABLET 4 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68258-6100 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-294 TABLET, FILM COATED, EXTENDED RELEASE 1 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-295 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-296 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-329 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 20 sections